Citius Oncology (CTOR) Competitors $1.81 -0.25 (-12.14%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$1.86 +0.05 (+2.76%) As of 08/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock CTOR vs. AVBP, MNMD, ABUS, AUTL, GYRE, MGTX, VALN, ZVRA, REPL, and EOLSShould you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include ArriVent BioPharma (AVBP), Mind Medicine (MindMed) (MNMD), Arbutus Biopharma (ABUS), Autolus Therapeutics (AUTL), Gyre Therapeutics (GYRE), MeiraGTx (MGTX), Valneva (VALN), Zevra Therapeutics (ZVRA), Replimune Group (REPL), and Evolus (EOLS). These companies are all part of the "pharmaceutical products" industry. Citius Oncology vs. Its Competitors ArriVent BioPharma Mind Medicine (MindMed) Arbutus Biopharma Autolus Therapeutics Gyre Therapeutics MeiraGTx Valneva Zevra Therapeutics Replimune Group Evolus Citius Oncology (NASDAQ:CTOR) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment. Do insiders and institutionals believe in CTOR or AVBP? 70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 4.6% of Citius Oncology shares are owned by company insiders. Comparatively, 18.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to CTOR or AVBP? In the previous week, Citius Oncology's average media sentiment score of 0.00 equaled ArriVent BioPharma'saverage media sentiment score. Company Overall Sentiment Citius Oncology Neutral ArriVent BioPharma Neutral Which has more volatility & risk, CTOR or AVBP? Citius Oncology has a beta of 3, suggesting that its stock price is 200% more volatile than the S&P 500. Comparatively, ArriVent BioPharma has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Which has better valuation and earnings, CTOR or AVBP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius OncologyN/AN/AN/AN/AN/AArriVent BioPharmaN/AN/A-$80.49M-$3.77-5.16 Do analysts recommend CTOR or AVBP? Citius Oncology presently has a consensus price target of $3.00, indicating a potential upside of 65.75%. ArriVent BioPharma has a consensus price target of $39.29, indicating a potential upside of 101.98%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe ArriVent BioPharma is more favorable than Citius Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Oncology 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00ArriVent BioPharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Is CTOR or AVBP more profitable? ArriVent BioPharma's return on equity of -49.21% beat Citius Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Citius OncologyN/A -53.88% -18.86% ArriVent BioPharma N/A -49.21%-46.61% SummaryArriVent BioPharma beats Citius Oncology on 6 of the 9 factors compared between the two stocks. Get Citius Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTOR vs. The Competition Export to ExcelMetricCitius OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$161.44M$3.07B$5.59B$9.53BDividend YieldN/A2.41%4.73%4.14%P/E RatioN/A17.5328.9123.88Price / SalesN/A313.17445.5998.82Price / CashN/A42.6035.6858.35Price / Book2.837.828.165.60Net IncomeN/A-$54.52M$3.25B$265.26M7 Day Performance-16.20%2.86%1.17%-0.14%1 Month Performance-65.98%17.29%8.27%6.08%1 Year PerformanceN/A13.27%29.19%24.22% Citius Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTORCitius Oncology0.9643 of 5 stars$1.81-12.1%$3.00+65.7%N/A$161.44MN/A0.00N/AGap DownAVBPArriVent BioPharma1.6509 of 5 stars$18.78+0.6%$39.29+109.2%-7.6%$638.41MN/A-4.9840Upcoming EarningsMNMDMind Medicine (MindMed)2.1028 of 5 stars$9.36+10.9%$24.71+164.0%+29.0%$637.67MN/A-6.1240News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap UpABUSArbutus Biopharma2.1922 of 5 stars$3.34+2.1%$5.50+64.7%-5.8%$626.29M$6.17M-8.1590Positive NewsUpcoming EarningsAUTLAutolus Therapeutics2.7501 of 5 stars$2.38+1.3%$9.32+291.6%-44.2%$625.43M$10.12M-2.70330News CoverageUpcoming EarningsGYREGyre TherapeuticsN/A$7.02+5.6%N/A-31.7%$623.49M$105.76M351.1840News CoverageUpcoming EarningsMGTXMeiraGTx4.4247 of 5 stars$7.84+2.5%$24.00+206.1%+73.9%$614.79M$33.28M-3.38300Upcoming EarningsVALNValneva2.6995 of 5 stars$7.50+3.9%$15.50+106.7%+15.9%$614.24M$183.52M-6.30700Upcoming EarningsGap UpZVRAZevra Therapeutics2.0937 of 5 stars$11.25+1.3%$23.71+110.8%+45.2%$607.49M$23.61M-5.9220Upcoming EarningsShort Interest ↑REPLReplimune Group4.3664 of 5 stars$5.71-24.9%$7.67+34.3%-35.0%$591.34MN/A-1.86210Trending NewsEOLSEvolus3.6914 of 5 stars$9.11-0.4%$23.75+160.7%-33.1%$589.95M$266.27M-10.24170News Coverage Related Companies and Tools Related Companies ArriVent BioPharma Competitors Mind Medicine (MindMed) Competitors Arbutus Biopharma Competitors Autolus Therapeutics Competitors Gyre Therapeutics Competitors MeiraGTx Competitors Valneva Competitors Zevra Therapeutics Competitors Replimune Group Competitors Evolus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTOR) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTOR Stock Alerts